Как работает иммунитет

Джессика Снейдер Сакс. «Микробы хорошие и плохие» М.: АСТ: CORPUS, 2014. – 496 c.

Eberl G., Lochner M. The development of intestinal lymphoid tissues at the interface of self and microbiota // Mucosal Immunol. 2009. Vol. 2, № 6. P. 478–485.

Jung C., Hugot J-P., Barreau F. Peyer’s patches: the immune sensors of the intestine // Int J Inflam. 2010; Vol. 2010. Article 823710.

Hemarajata P., Versalovic J.Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation // Therap Adv Gastroenterol. 2013. Vol. 6, № 1. P. 39–51.

Bender D.A. Nutritionalbiochemistryofthevitamins. Cambridge, U.K.: CambridgeUniversityPress. 2003. 488 pp..

Mora J.R., Iwata M., von Andrian U.H. Vitamin effects on the immune system: vitamins A and D take centre stage // Nat Rev Immunol. 2008. Vol. 8, № 9, P.685–698.

World Health Organization, Food and Agricultural Organization of the United Nations. Vitamin and mineral requirements in human nutrition. Second edition. 2004. 341 pp..

http://www.who.int/vmnis/ru/.

Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group, authors. // Lancet. 1991. Vol. 338. P. 131–137; Rieder M.J. Prevention of neural tube defects with periconceptional folic acid. // Clin Perinatol. 1994. Vol. 21. P. 483–503; Pitkin RM. Folate and neural tube defects. // Am J Clin Nutr. 2007. Vol. 85. P. 285S–288S; De Wals P, Tairou F, Van Allen MI, et al. Reduction in neural-tube defects after folic acid fortification in Canada. // N Engl J Med. 2007. Vol. 357. P. 135–142.

Hamishehkar H., Ranjdoost F., Asgharian P., Mahmoodpoor A., Sanaie S. Vitamins, Are They Safe? // Adv Pharm Bull, 2016. Vol. 6, № 4. P. 467–477.

Hemilä H.Vitamin C and the common cold // British Journal of Nutrition. 1992. Vol. 67. P. 3–16.

Cowan D.W., Dieh H.S., Baker A.B. Vitamins for the prevention of colds // JAMA. 1942. Vol.120, № 16, P. 1268–1271.

Hemilä H., Chalker E. VitaminCforpreventingandtreatingthecommoncold // CochraneDatabaseSystRev. 2013. № 1. CD000980.

Lonn E., Bosch J., Yusuf S., Sheridan P., Pogue J., Arnold J.M., Ross C., Arnold A., Sleight P., Probstfield J., Dagenais G.R. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial // JAMA. 2005. Vol. 293, № 11. P. 1338–1347; Bjelakovic G., Nikolova D., Gluud L.L., Simonetti R.G., Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases // Cochrane Database Syst Rev. 2012. № 3. CD007176.

Martínez M.E., Jacobs E.T., Baron J.A., Marshall J.R., Byers T. Dietary supplements and cancer prevention: balancing potential benefits against proven harms // J Natl Cancer Inst. 2012. Vol. 104, № 10. P. 732–739; Klein E.A., Thompson I.M., Tangen C.M., et al. Vitamin E and the risk of prostate cancer. The Selenium and vitamin E cancer prevention trial (SELECT) // JAMA. 2011. Vol. 306, № 14. P. 1549–1556; Miller E.R. 3rd, Pastor-Barriuso R., Dala D., Riemersma R.A., Appel L.J., Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality //Ann Intern Med. 2005. Vol. 142, № 1, P. 37–46; Lawson K.A., Wright M.E., Subar A., Mouw T., Hollenbeck A., Schatzkin A., Leitzmann M.F.Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study // J Natl Cancer Inst. 2007. Vol. 99, № 10, P. 754–764; Park S-Y., Murphy S.P., Wilkens L.R., Henderson B.E., Kolonel L.N. Multivitamin use and the risk of mortality and cancer incidence the multiethnic cohort study // Am J Epidemiol. 2011. Vol.173, № 8. P. 906–914.

Randall K.L. Rituximabinautoimmunediseases // AustPrescr. 2016. Vol. 39, № 4. P. 131–134; Vital E.M., Emery P. Abatacept in the treatment of rheumatoid arthritis // Ther Clin Risk Manag. 2006. Vol. 2, № 4. P. 365–375; Dubey A.K., Handu S.S., Dubey S., Sharma P., Sharma K.K., Ahmed Q.M. Belimumab: First targeted biological treatment for systemic lupus erythematosus // J Pharmacol Pharmacother. 2011. Vol. 2, № 4, P.317–319.

Quach H., Ritchie D., Stewart A.K., Neeson P., Harrison S., Smyth M.J., Prince H.M. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma // Leukemia. 2010. Vol. 24, № 1. P. 22–32; Andhavarapu S., Roy V. Immunomodulatory drugs in multiple myeloma // Expert Review of Hematology. 2013. Vol. 6, № 1. P. 69–82; Sedlarikova L., Kubiczkova L., Sevcikova S., Hajek R. (October 2012). Mechanism of immunomodulatory drugs in multiple myeloma // Leukemia Research. 2012. Vol. 36, № 10. P. 1218–1224.

Chang X.B., Stewart A.K. What is the functional role of the thalidomide binding protein cereblon? // International Journal of Biochemistry and molecular biology. 2011. Vol. 2, № 3. P. 287–294.

Baldo B.A. Side effects of cytokines approved for therapy. // Drug Saf. 2014. Vol. 37. P. 921–943.

Baldo B.A. Side effects of cytokines approved for therapy. // Drug Saf. 2014. Vol. 37. P. 921–943.